# US 2004/0023863 A1 · Methods of use growth factors for treating heart disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0023863 A1
- Document ID: US20040023863A1
- Status: Published application
- Kind: A1
- Application number: 10/239,902
- Filed: 2003-01-23
- Published: 2004-02-05
- Earliest claimed: 2000-04-06
- Inventors: Wayne P. Franco
- Web page: https://patentgrep.com/patent/US20040023863A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61K 38/1866: {Vascular endothelial growth factor [VEGF]}
- G01N 2800/32: Cardiovascular disorders
- G01N 2800/324: Coronary artery diseases, e.g. angina pectoris, myocardial infarction
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.

## Claims

### Claim 1

A method for the systematic multi-tiered treatment of heart disease by delivery of therapeutic growth factor proteins comprising the steps of:
a.) selecting a patient displaying symptoms of heart disease;
b.) administering at least one dose of an effective amount of a first therapeutic growth factor protein formulation by oral inhalation;
c.) monitoring levels of CPK-MB in the patient;
d.) determining whether administration of the growth factor protein formulation was effective in treating the symptoms of heart disease in the patient;
e.) administering one or more additional doses of a second growth factor protein formulation by a method of delivery more invasive than delivery by oral inhalation; and
f.) repeating steps c.) through e.) until there is a clinical indication of amelioration of the symptoms of heart disease in the patient, or until there is a contraindication to continued treatment.

### Claim 2 (depends on 1)

The method of claim 1, wherein the protein formulation comprises a growth factor protein selected from the group consisting of FGF-1, FGF-2, VEGF, and mixtures thereof.

### Claim 3 (depends on 1)

The method of claim 1 wherein the symptoms of heart disease are acute.

### Claim 4 (depends on 3)

The method of claim 3 wherein the acute symptoms of heart disease are brought on by a condition selected from the group consisting of myocardial infarct, unstable angina, an acute anginal attack, and reperfusion injury.

### Claim 5 (depends on 4)

The method of claim 4, wherein the reperfusion injury is induced by a procedure selected from the group consisting of thrombolytic therapy, bypass surgery and angioplasty.

### Claim 6 (depends on 1)

The method of claim 1 wherein the symptoms of heart disease are chronic.

### Claim 7

A method for the administration of therapeutic amounts of a growth factor protein formulation in the treatment of heart disease comprising the step of delivering the protein formulation by inhalation therapy.

### Claim 8 (depends on 7)

The method of claim 7, wherein the protein formulation is a dry powder formulation.

### Claim 9 (depends on 7)

The method of claim 7, wherein the protein formulation is a liquid aerosol formulation.

### Claim 10

A method for monitoring clinical effectiveness of administration of a growth factor protein formulation in the treatment of heart disease, the method comprising the steps of:
a.) obtaining a sample of a biological fluid from a patient displaying symptoms of heart disease;
b.) performing an assay of the biological fluid to determine an amount of CPK-MB present in the fluid;
c.) administering a therapeutic amount of a growth factor protein formulation to the patient; and
d.) repeating steps b.) and c.) until the assayed amount of CPK-MB in the biological fluid has decreased by an amount sufficient to indicate the clinical effectiveness of the administration of the growth factor protein formulation.

### Claim 11 (depends on 10)

The method of claim 10, wherein the protein formulation comprises a growth factor protein selected from the group consisting of FGF-1, FGF-2, VEGF, and mixtures thereof.

### Claim 12 (depends on 10)

The method of claim 10 wherein the heart disease is characterized by acute symptoms.

### Claim 13 (depends on 12)

The method of claim 12 wherein the acute symptoms of heart disease are brought on by a condition selected from the group consisting of myocardial infarct, unstable angina, an acute anginal attack, and reperfusion injury.

### Claim 14 (depends on 13)

The method of claim 13, wherein the reperfusion injury is induced by a procedure selected from the group consisting of thrombolytic therapy, bypass surgery and angioplasty.

### Claim 15 (depends on 10)

The method of claim 10 wherein the heart disease is characterized by symptoms that are chronic.
